Repurposing AS1411 for constructing ANM-PROTACs
- 23 April 2024
- journal article
- research article
- Published by Elsevier in Cell Chemical Biology
- Vol. 31 (7) , 1290-1304.e7
Abstract
No abstract availableKeywords
Funding Information
- Southern University of Science and Technology
This publication has 66 references indexed in Scilit:
- Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTACClinical and Translational Medicine, 2023
- Dual-specificity RNA aptamers enable manipulation of target-specific O-GlcNAcylation and unveil functions of O-GlcNAc on β-cateninCell, 2023
- Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast CancerAngewandte Chemie International Edition, 2021
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In VivoCancer Cell, 2019
- Structural simplification: an efficient strategy in lead optimizationActa Pharmaceutica Sinica B, 2019
- Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcomaBiomaterials, 2017
- Transcription factor decoy technology: A therapeutic updateBiochemical Pharmacology, 2017
- G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanismsBiochimica et Biophysica Acta (BBA) - General Subjects, 2017
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinomaInvestigational New Drugs, 2013
- Lack of toxicity of a STAT3 decoy oligonucleotideCancer Chemotherapy and Pharmacology, 2008